We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

DIESSE DIAGNOSTICA SENESE SPA

DIESSE Diagnostica Senese S.P.A. manufactures in-vitro diagnostics systems for the hematology, seroimmunology and bac... read more Featured Products: More products

Download Mobile App





DIESSE Diagnostica Unveils CHORUS EVO Immunochemistry Analyzer

By LabMedica International staff writers
Posted on 25 May 2023
Print article
Image: The CHORUS EVO immunochemistry analyzer features innovative digital technologies (Photo courtesy of Diesse Diagnostica)
Image: The CHORUS EVO immunochemistry analyzer features innovative digital technologies (Photo courtesy of Diesse Diagnostica)

Diesse Diagnostica Senese S.p.A. (Rigoni, Italy) is unveiling its new innovative immunochemistry analyzer, the CHORUS EVO, at this year's WorldLab-EuroMedLab.

The cutting-edge DIESSE CHORUS line comprises a compact instrument and consumables for immunometric assays. Known for simplicity, high-quality mono-test results, and reliability, the CHORUS line is the perfect tool for conducting small-batch diagnostic tests. Its design ensures maximum flexibility in managing the workflow of a clinical laboratory. Even when lab automation isn't viable, the CHORUS line stands out as a go-to solution for immediate, simple, and accurate testing. Its mono-test format facilitates operational efficiency and minimal waste, which is a boon for smaller test volumes. This makes CHORUS an excellent resource for Physician Office Laboratories (POLs) and other diagnostic laboratories, providing them with analytical quality and operational efficiency.

In line with developing instruments featuring cutting-edge technology that meet Italian design and its vision of "Diagnostics Evolution", DIESSE has now unveiled the CHORUS EVO immunochemistry analyzer. CHORUS EVO is a new-generation analytical instrument that integrates innovative digital technology, paving the way for the integration of artificial intelligence functions. In order to achieve this, DIESSE is collaborating with the SAIHUB consortium, a network of companies that specialize in applying artificial intelligence in life sciences.

Their collaborative effort is directed towards creating a data platform, to which the instruments will be connected, facilitating a large-scale data accumulation. This setup will enable direct digital communication between the company and individual instruments, making it possible for the company to monitor the instruments through the data platform. Moreover, it will harness beneficial artificial intelligence functions to train the analyzers to enhance their performance and employ predictive diagnostics to preempt machine downtime. The project also plans to incorporate computer vision systems rooted in artificial intelligence to further optimize the diagnostic capabilities of the instruments.

Related Links:
Diesse Diagnostica Senese Spa

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Hemoglobin Testing System
VARIANTnbs

Print article
77 ELEKTRONIKA

Channels

Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more

Molecular Diagnostics

view channel
Image: Researchers have found the first evidence of testing for the alpha-synuclein protein in blood samples via seed amplification assay (Photo courtesy of Shutterstock)

Blood Test to Detect Alpha-Synuclein Protein Could Revolutionize Parkinson's Disease Diagnostics

Currently, Parkinson's disease (PD) is identified through clinical diagnosis, typically at a later stage in the disease's progression. There is a pressing need for an objective and quantifiable biomarker... Read more

Hematology

view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more

Immunology

view channel
Image: The blood test measures lymphocytes  to guide the use of multiple myeloma immunotherapy (Photo courtesy of 123RF)

Simple Blood Test Identifies Multiple Myeloma Patients Likely to Benefit from CAR-T Immunotherapy

Multiple myeloma, a type of blood cancer originating from plasma cells in the bone marrow, sees almost all patients experiencing a relapse at some stage. This means that the cancer returns even after initially... Read more

Microbiology

view channel
Image: Ultra-Rapid Antimicrobial Susceptibility Testing (uRAST) revolutionizing traditional antibiotic susceptibility testing (Photo courtesy of Seoul National University)

Ultra-Rapid Culture-Free Sepsis Test Reduces Testing Time from Days to Hours

Sepsis, a critical emergency condition, results from an overactive inflammatory response to pathogens like bacteria or fungi in the blood, leading to organ damage and the possibility of sudden death.... Read more

Pathology

view channel
Image: The AI model can distinguish different stages of DCIS from inexpensive and readily available breast tissue images (Photo courtesy of David A. Litman/Shutterstock)

AI Model Identifies Breast Tumor Stages Likely To Progress to Invasive Cancer

Ductal carcinoma in situ (DCIS) is a non-invasive type of tumor that can sometimes progress to a more lethal form of breast cancer and represents about 25% of all breast cancer cases. Between 30% and 50%... Read more

Industry

view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.